WASHINGTON — Gilead Sciences has priced its Covid-19 drug candidate remdesivir at US$390 (S$543) per vial for the United States and governments of other developed countries, it said on Monday (June 29), setting the price of a five-day course at $2,340 (S$3,258) per patient.
The price for US private insurance companies will be US$520 per vial, the drugmaker said, which equates to a total of US$3,120 per patient.
Experts have suggested that Gilead would need to avoid the appearance of taking advantage of a health crisis for profits.
Wall Street analysts have said the antiviral drug could generate billions of dollars in revenue over the next couple of years if the pandemic continues. REUTERS